Kynam Capital Management, LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Kynam Capital Management, LP reported 24 stock positions worth $1.3 billion. Its top holding was Natera (NTRA) at 20.1% of the portfolio, followed by Vaxcyte (PCVX, 9.2%) and Celldex Therapeutics (CLDX, 9.1%). Compared with Q2 2024, it opened 2 new positions, added to 17 and reduced 4. The biggest buy was CG Oncology (CGON, shares +3185%) and the biggest sale Protagonist Therapeutics (PTGX, shares −43%).
- Most Recent 13F
- Q2 2026
- Location
- PRINCETON, NJ
- CIK
- 0001907884
- Portfolio Value
- $1.3B (Q3 2024)
- SEC Filing
- 0001085146-24-005812 ↗ filed Nov 14, 2024
Holdings Value
Holdings 24 stocks · $1.3B
| NTRA Natera Inc. | 20.09% | 2,042,471 | $259.3M | Add +1.4% |
| PCVX Vaxcyte Inc. | 9.20% | 1,039,288 | $118.8M | Add +38.0% |
| CLDX Celldex Therapeutics Inc. | 9.11% | 3,458,609 | $117.6M | Add +2.0% |
| SNDX Syndax Pharmaceuticals Inc. | 8.72% | 5,842,925 | $112.5M | Add +2.1% |
| COGT Cogent Biosciences Inc. | 7.73% | 9,239,731 | $99.8M | Reduce -0.2% |
| DVAX Dynavax Technologies Corp. | 7.19% | 8,332,687 | $92.8M | Add +17.6% |
| VERA Vera Therapeutics Inc. | 5.40% | 1,576,549 | $69.7M | Add +2.1% |
| BCRX Biocryst Pharmaceuticals Inc. | 5.35% | 9,085,368 | $69.0M | Add +2.9% |
| CGON CG Oncology Inc. | 5.18% | 1,770,805 | $66.8M | Add +3184.7% |
| VRDN Viridian Therapeutics Inc. | 4.43% | 2,511,295 | $57.1M | Add +43.5% |
| WVE Wave Life Sciences Ltd. | 3.11% | 4,899,497 | $40.2M | Add +23.2% |
| BEAM Beam Therapeutics Inc. | 2.47% | 1,302,085 | $31.9M | New |
| TSVT 2SEVENTY Bio Inc. | 2.18% | 5,953,825 | $28.1M | No change |
| LQDA Liquidia Corp. | 1.76% | 2,266,328 | $22.7M | Add +147.3% |
| PTGX Protagonist Therapeutics Inc. | 1.59% | 456,369 | $20.5M | Reduce -43.0% |
| TVTX Travere Therapeutics Inc. | 1.49% | 1,371,511 | $19.2M | Reduce -32.2% |
| IRWD Ironwood Pharmaceuticals Inc. | 1.18% | 3,685,563 | $15.2M | Add +124.5% |
| ENGN Engene Holdings Inc. | 0.89% | 1,736,227 | $11.5M | New |
| TYRA Tyra Biosciences Inc. | 0.85% | 467,947 | $11.0M | Reduce -17.4% |
| AMARIN CORP PLC | 0.60% | 12,414,628 | $7.8M | Add +2.1% |
| STRO Sutro Biopharma Inc. Com SHS | 0.55% | 2,066,447 | $7.1M | Add +2.1% |
| CRBU Caribou Biosciences Inc. | 0.36% | 2,356,147 | $4.6M | Add +43.1% |
| SLRN Acelyrin Inc. | 0.32% | 847,366 | $4.2M | Add +1.9% |
| BNR Burning Rock Biotech Ltd.-ADR | 0.25% | 989,217 | $3.2M | Add +1.5% |
Options reported separately and not counted above: VRTX puts ($14.0M).
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| CGON CG Oncology Inc. | Add +3184.7% | 5.18% | +5.00 |
| PCVX Vaxcyte Inc. | Add +38.0% | 9.20% | +3.25 |
| BEAM Beam Therapeutics Inc. | New | 2.47% | +2.47 |
| VRDN Viridian Therapeutics Inc. | Add +43.5% | 4.43% | +2.04 |
| WVE Wave Life Sciences Ltd. | Add +23.2% | 3.11% | +1.04 |
| ENGN Engene Holdings Inc. | New | 0.89% | +0.89 |
| LQDA Liquidia Corp. | Add +147.3% | 1.76% | +0.60 |
| CRBU Caribou Biosciences Inc. | Add +43.1% | 0.36% | +0.08 |
| IRWD Ironwood Pharmaceuticals Inc. | Add +124.5% | 1.18% | +0.06 |
| SLRN Acelyrin Inc. | Add +1.9% | 0.32% | −0.06 |
| STRO Sutro Biopharma Inc. Com SHS | Add +2.1% | 0.55% | −0.07 |
| AMARIN CORP PLC | Add +2.1% | 0.60% | −0.27 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +2.9% | 5.35% | −0.36 |
| BNR Burning Rock Biotech Ltd.-ADR | Add +1.5% | 0.25% | −0.41 |
| VERA Vera Therapeutics Inc. | Add +2.1% | 5.40% | −0.45 |
| DVAX Dynavax Technologies Corp. | Add +17.6% | 7.19% | −1.13 |
| NTRA Natera Inc. | Add +1.4% | 20.09% | −2.75 |
| SNDX Syndax Pharmaceuticals Inc. | Add +2.1% | 8.72% | −3.58 |
| CLDX Celldex Therapeutics Inc. | Add +2.0% | 9.11% | −4.02 |
Options Activity Q2 2024 → Q3 2024
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 200,000 | $109.1Mbefore exit |
| INSM Insmed Inc. | call | Sold out | 1,000,000 | $67.0Mbefore exit |
| VRTX Vertex Pharmaceuticals Inc. | put | Reduce -90.9% | 30,000 | $14.0M |
| ALNY Alnylam Pharmaceuticals Inc. | put | Sold out | 43,000 | $10.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $1.8B | CLDX, SNDX, PCVX, COGT, VERA |
| Q1 2026 | 36 | $1.6B | SNDX, CLDX, PCVX, COGT, VERA |
| Q4 2025 | 35 | $1.5B | COGT, VERA, SNDX, CLDX, PCVX |
| Q3 2025 | 35 | $1.3B | CLDX, SNDX, VERA, COGT, PCVX |
| Q2 2025 | 31 | $928.8M | CLDX, PCVX, VERA, SNDX, BCRX |
| Q1 2025 | 31 | $1.2B | NTRA, PCVX, CLDX, SNDX, BCRX |
| Q4 2024 | 29 | $1.5B | NTRA, PCVX, CLDX, SNDX, DVAX |
| Q3 2024 | 24 | $1.3B | NTRA, PCVX, CLDX, SNDX, COGT |
| Q2 2024 | 22 | $955.2M | NTRA, CLDX, SNDX, DVAX, COGT |
| Q1 2024 | 21 | $898.9M | NTRA, SNDX, CLDX, VERA, COGT |